Amlitelimab Demonstrates Durable Disease Control in Moderate-to-Severe Atopic Dermatitis: Phase 2b STREAM-AD Findings

The Quest for Long-term Atopic Dermatitis Management

Atopic dermatitis (AD), a chronic skin disease marked by intense itching and recurrent lesions, continues to impose significant disease burden and compromise quality of life. Despite the availability of biologics and Janus kinase inhibitors targeting type 2 inflammation, sustained disease control remains challenging. Rapid return of symptoms following therapy withdrawal and safety limitations of broad immunomodulators underscore the need for new treatments that offer both long-term efficacy and an improved safety profile.

Targeting T-cell Costimulation: The Rationale Behind Amlitelimab

The OX40 ligand (OX40L)-OX40 pathway has recently emerged as a critical driver of chronic T-cell–mediated inflammation in AD, promoting the persistence of multiple inflammatory T-cell types. Amlitelimab (SAR445229, KY1005) is a fully human, non-depleting IgG4 monoclonal antibody directed against OX40L, aiming to inhibit pathogenic T-cell activation at the antigen-presenting cell (APC)–T cell interface without lymphocyte depletion. Early-phase trials have suggested the potential of amlitelimab for durable improvements in AD lesions and pruritus, warranting further investigation.

Study Design: STREAM-AD Phase 2b at a Glance

The STREAM-AD study (NCT05131477) was a rigorous multicenter, double-blind, placebo-controlled phase 2b trial conducted across 100 sites in 12 countries. Adults with moderate-to-severe AD who had not responded adequately to topical therapies were randomized to receive subcutaneous injections every four weeks: either varying doses of amlitelimab or placebo.

The trial consisted of a 24-week treatment phase (Part 1), followed by a 28-week maintenance/withdrawal phase (Part 2). Responders at week 24—those achieving at least a 75% reduction in Eczema Area and Severity Index (EASI) or an Investigator Global Assessment (IGA) of 0 or 1—were rerandomized in a 3:1 ratio to continue or stop amlitelimab for up to week 52.

Efficacy Endpoints: Clinical and Biomarker Outcomes

The primary endpoint was the percentage change in EASI from baseline to week 16. Key secondary endpoints included EASI change at week 24, proportions achieving EASI-75 and IGA 0/1, and pruritus improvement, using rigorous prespecified imputation strategies to handle rescue medication use and discontinuations.

Outcomes also included biomarker assessments (e.g., serum IgE, IL-13, IL-22, IL-17A, IL-31, TARC) and safety analyses, with adverse events monitored throughout.

Patient Population and Methodology

Of 390 randomized patients, 388 were treated, with balanced baseline characteristics across arms. The mean patient age was 37.8 years, and around 56% were male. Responders from all groups (amlitelimab and placebo) were rerandomized at week 24 for the subsequent withdrawal analysis; non-responders were eligible for a long-term extension.

Key Findings: Durable Efficacy and Reduced Biomarker Levels

Amlitelimab met its primary endpoint, achieving a statistically significant reduction in EASI at week 16 compared to placebo. Secondary endpoints at week 24 confirmed superior improvements in AD lesions, pruritus, and quality of life among amlitelimab recipients. Notably, no linear dose-response was observed, though the 250 mg + loading dose regimen tended to yield greater numerical improvements.

Long-term observations revealed maintained clinical responses in the majority of patients—both with ongoing treatment and after cessation of therapy—for up to 32 weeks post-last injection. This extended benefit was paralleled by reductions in TH2 and TH17/22 biomarker levels, which persisted even as serum amlitelimab concentrations became negligible, raising questions about the mechanism behind the durable effect.

Safety Profile: Tolerability Across Doses

Amlitelimab was generally well tolerated across all dosing regimens over 52 weeks, with no significant dose-dependent safety issues identified. Serious adverse events and discontinuations were infrequent, and rates of events such as aphthous ulcers, pyrexia, and conjunctivitis were balanced across groups, consistent with a non–T-cell–depleting mechanism of action.

Implications for Clinical Practice and Future Research

The potential to achieve disease control with extended dosing intervals—possibly as infrequently as every 12 weeks—is a significant advantage for patients and clinicians. This could reduce treatment burden and address unmet needs in chronic disease management. Furthermore, sustained clinical benefit after amlitelimab discontinuation hints at possible restoration of immune balance or modification of disease mechanisms, meriting further mechanistic studies.

Could these findings shift current therapeutic paradigms for moderate-to-severe AD, favoring OX40L–OX40 modulation over existing approaches? What additional insights could be gained from real-world, diverse populations or from exploring the exact durability mechanism?

Looking Ahead: Limitations and Future Directions

While promising, the study's withdrawal phase was limited by small sample size and geographic homogeneity. The ongoing phase 3 program aims to include a larger, more diverse cohort and will further examine extended dosing intervals. Detailed investigation of immunologic mechanisms underlying durable remission will be key to guiding future trial designs and optimizing therapeutic strategies.

How will regulators view the implications of persistent efficacy post-treatment, especially around long-term immune modulation? What real-world challenges might arise in translating these findings into clinical practice?